Photothermal-controlled NO-releasing Nanogels reverse epithelial-mesenchymal transition and restore immune surveillance against cancer metastasis
Journal of Controlled Release · 2024-07 · 371 · 16-28
DOI: 10.1016/j.jconrel.2024.05.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-07. Verfasst von Junmei Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Nitric Oxide, Nanogels, Mice, Inbred BALB C. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Metastasis leads to high mortality among cancer patients. It is a complex, multi-step biological process that involves the dissemination of cancer cells from the primary tumor and their systemic spread throughout the body, primarily through the epithelial-mesenchymal transition (EMT) program and immune evasion mechanisms. It presents a challenge in how to comprehensively treat metastatic cancer cells throughout the entire stage of the metastatic cascade using a simple system. Here, we fabricate a nanogel (HNO-NG) by covalently crosslinking a macromolecular nitric oxide (NO) donor with a photothermal IR780 iodide-containing hyaluronic acid derivative via a click reaction. This enables stable storage and tumor-targeted, photothermia-triggered release of NO to combat tumor metastasis throughout all stages. Upon laser irradiation (HNO-NG+L), the surge in NO production within tumor cells impairs the NF-κB/Snail/RKIP signaling loop that promotes the EMT program through S-nitrosylation, thus inhibiting cell dissemination from the primary tumor. On the other hand, it induces immunogenic cell death (ICD) and thereby augments anti-tumor immunity, which is crucial for killing both the primary tumor and systemically distributed tumor cells. Therefore, HNO-NG+L, by fully leveraging EMT reversal, ICD induction, and the lethal effect of NO, achieved impressive eradication of the primary tumor and significant prevention of lung metastasis in a mouse model of orthotropic 4T1 breast tumor that spontaneously metastasizes to the lungs, extending the NO-based therapeutic approach against tumor metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
- Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China; Engineering Research Center for Smart Pharmaceutical Manufacturing Technologies, Ministry of Educa…
- Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Electronic address: ynzhong@cpu.edu.cn.
Zitieren
APA
Zhang, J., Miao, G., Ta, M. H., Zhao, B., Wang, W., Xing, Y., Qian, H., Huang, D., Chen, W., & Zhong, Y. (2024). Photothermal-controlled NO-releasing Nanogels reverse epithelial-mesenchymal transition and restore immune surveillance against cancer metastasis. Journal of Controlled Release, 371, 16-28. https://doi.org/10.1016/j.jconrel.2024.05.028
Vancouver
Zhang J, Miao G, Ta MH, Zhao B, Wang W, Xing Y, et al. Photothermal-controlled NO-releasing Nanogels reverse epithelial-mesenchymal transition and restore immune surveillance against cancer metastasis. Journal of Controlled Release. 2024;371:16-28. doi:10.1016/j.jconrel.2024.05.028
BibTeX
@article{Zhang2024,
author = {Zhang, Junmei and Miao, Guizhi and Ta, My Hanh and Zhao, Bingbing and Wang, Wei and Xing, Yanran and Qian, Hongliang and Huang, Dechun and Chen, Wei and Zhong, Yinan},
title = {Photothermal-controlled NO-releasing Nanogels reverse epithelial-mesenchymal transition and restore immune surveillance against cancer metastasis},
journal = {Journal of Controlled Release},
year = {2024},
volume = {371},
pages = {16--28},
doi = {10.1016/j.jconrel.2024.05.028}
}
EUVIMED